Dishman Carbogen Amcis Limited Announces Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2018
January 23, 2019 at 01:04 pm IST
Share
Dishman Carbogen Amcis Limited announced unaudited standalone and consolidated earnings results for third quarter and nine months ended December 31, 2018. For the quarter, the company reported standalone net sales/income from operations were INR 1,135.6 million against net sales/income from operations of INR 766.1 million a year ago. Net Loss after tax was INR 31.1 million against net profit after tax of INR 117.4 million a year ago. Basic loss per share was INR 0.19 against basic earnings per share of INR 0.73 a year ago.
For the period, the company reported standalone net sales/income from operations were INR 3,357.2 million against net sales/income from operations of INR 2,938.8 million a year ago. Net profit after tax was INR 271.3 million against net profit after tax of INR 256.4 million a year ago. Basic earnings per share was INR 1.68 against basic earnings per share of INR 1.59 a year ago.
For the quarter, the company reported consolidated net sales/income from operations were INR 4,273.9 million against net sales/income from operations of INR 4,309.1 million a year ago. Net profit after tax was INR 513.7 million against net profit after tax of INR 420 million a year ago. Basic earnings per share was INR 3.18 against basic earnings per share of INR 2.6 a year ago.
For the period, the company reported consolidated net sales/income from operations were INR 13,085.2 million against net sales/income from operations of INR 12,001.6 million a year ago. Net profit after tax was INR 1,349.9 million against net profit after tax of INR 1,034.1 million a year ago. Basic earnings per share was INR 8.36 against basic earnings per share of INR 6.41 a year ago.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Dishman Carbogen Amcis Limited Announces Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2018